Nuo Therapeutics: amends loan and receives $325,000

What happened The filing reports that effective Oct 6, 2026, Nuo Therapeutics entered into an Assignment, Joinder, and Amendment No. 1 to its Amended and Restated Loan and Security Agreement and the Second Funding closed on Oct 6, 2026, with the Company receiving $325,000. The filing also reports that, effective Sep 30, 2026, the Company had entered into a Consent and Extension to the loan agreement solely to extend the Second Closing Date prior to the Oct 6, 2026 Amendment. The filing states the Company has received an aggregate of $2,000,000 from lenders under the Loan Agreement.

Key details

• The Amendment changed the Second Closing Date to Oct 6, 2026 and enabled a Lender to assign a $100,000 portion of its Second Funding commitment.
• The $100,000 assigned portion was assumed in equal $25,000 portions by four assuming lenders: three new, unaffiliated persons and Scott M. Pittman, a director and more than 10% beneficial owner.
• The Company issued Secured Promissory Notes for the Second Funding bearing interest at 12% per year, with a maturity date of Dec 31, 2028, and interest payable in warrants.
• The assuming lenders received, for their aggregate $100,000: Second Restated Warrants exercisable for 18,000 shares immediately, Prepayment Restated Warrants exercisable for 1,832 shares subject to contingent vesting, and Interest Warrants exercisable for up to 11,000 shares at the Maturity Date (or earlier upon prepayment). Mr. Pittman received Second Restated Warrants for 4,500 shares, Prepayment Restated Warrants for 458 shares (subject to vesting), and an additional Interest Warrant for up to 2,750 shares.

Why it may matter This item is reported under Item 1.01 (entry into a material definitive agreement) and describes the Amendment and assignment to the Company’s Amended and Restated Loan and Security Agreement and the closing of the Second Funding. The filing also references Item 2.03 (creation of a direct financial obligation) and Item 3.02 (unregistered sales of equity securities) in connection with the notes and warrants issued.

The filing does not show why the insider traded or why the company acted.